This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Applied Stemcell, Inc., a minority-owned, woman-owned small business, for a firm-fixed-price purchase order in the amount of $63,000.00. The contract calls for the use of CRISPR gene editing technology to create two custom induced pluripotent stem cell (iPSC) reporter cell lines - one with dual gene knock-ins for albumin and alpha-fetoprotein, and...
Genscript USA Inc. has been awarded a $16,317 firm fixed price purchase order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide genomic editing knock-in services in support of the agency's GENCRISPR program. The contract calls for Genscript to deliver CRISPR/Cas9 gene editing services for the NIH's research on infectious diseases from its facility in Piscataway, New Jersey over a six-month period concluding in late February 2024. No...
This firm fixed-price purchase order, valued at $13,199.63, was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of HEK293 knockout cell lines, which are a critical resource for biomedical research supported by the NIDDK. Genscript USA Inc. is an experienced federal contractor, having received numerous prime and subcontract awards from...
This federal contract award, valued at $24,999.00, was issued by the National Institute of Child Health and Human Development (NICHD), a component of the U.S. Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in New Jersey. The contract requires Genscript to generate four stable cell lines, with a final completion date of March 11, 2022. This was a firm fixed-price purchase order, and there was no set-aside designation. Genscript has received...
This firm fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $15,289.00 contract will run through September 30, 2024 and does not have a set-aside designation. Genscript specializes in gene synthesis, gene editing, custom protein and antibody production, and other molecular biology services that support...
This firm fixed-price purchase order was awarded by the National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to GenScript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $65,963.22 contract is for gene synthesis and related services to support NICHD's research on how transcription factors regulate gene expression and chromatin structure. The award stems from a sole-source special notice solicitation, as NICHD...
This firm fixed-price purchase order, valued at $14,607.70, was awarded by the National Institute of Child Health and Human Development (NICHD) to Genscript USA Inc. for gene synthesis and cloning services. The ultimate completion date is August 29, 2024. Genscript is a biotechnology company based in Piscataway, New Jersey that specializes in molecular biology products and services to support biomedical research and public health initiatives for various federal agencies, including the National...
The Department of Health and Human Services' National Institutes of Health's National Institute of Child Health and Human Development awarded a $14,141.84 purchase order to Genscript USA Inc. for "OTHER FUNCTIONS - CUSTOMIZED GENE SYNTHESES" to be performed in Bethesda, Maryland between September 8-16, 2016. As a firm fixed price contract for customized gene synthesis services, Genscript will deliver specified genetic material to the NIH organization to support its biomedical...
This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company, for custom gene synthesis services. The contract has a potential value of $21,275.80 and a completion date of August 19, 2020. Genscript, based in Piscataway, New Jersey, specializes in gene synthesis, gene editing, custom protein and...
This firm fixed-price purchase order was awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $10,982.04 contract is for the provision of customized protein services, gene synthesis, and other molecular biology products and services to support biomedical research and public health initiatives. The contract does not...
This firm fixed-price purchase order for $18,204.88 was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Genscript USA Inc. to obtain cell lines utilizing CRISPR gene editing technology. Specifically, the contract calls for Genscript to generate knockout HEK293 and HepG2 cell lines of the MMAB and MUT genes to support studies for hereditary disorders of vitamin B12 and methylmalonic acid metabolism. No set-aside designation was used for this award. The work will provide deliverables to support the National Center for Advancing Translational Sciences' Platform Vector Gene Therapy project and is to be completed by August 2021, with an optional two-month extension for additional validation services.